High blood pressure is a risk factor which has been shown in well documented studies to be significantly associated with excess morbidity and mortality. For example, the Framingham study (Kannel, Wolf, Verter, and McNamara, 1970) showed an increased risk of cardiovascular and cerebrovascular disease in initially asymptomatic persons whose initial pressures were 160/90 mm Hg or greater. The worthwhileness of treating raised blood pressure has also been documented (Breckenridge, Dollery, and Parry, 1970) , particularly in respect of cerebrovascular disease and renal impairment, although there appears to be little if any influence on the incidence of myocardial infarction. The underlying pathogenesis of so-called 'essential hypertension' is still unknown, and this probably explains in part the plethora of drugs presently available for its treatment. Furthermore 2 Noradrenaline is depleted so that there is none available for release by the nerve impulse. This is the probable mechanism of action of reserpine and the other Rauwolfia alkaloids.
3 Noradrenaline synthesis is impaired, or a false transmitter is substituted for noradrenaline with a weaker pressor action, so that sympathetic nerve activity results in a reduced response. This mechanism may account, in part, for the antihypertensive action of methyldopa (Aldomet).
Troublesome side-effects of treatment with these drugs are due to relative parasympathetic overactivity in the gut and urogenital system producing diarrhoea and interference with sexual function. Nasal congestion, fluid retention, and mental depression also occur. Methyldopa produces a positive antiglobulin test in 20% of patients but clinical haemolysis is rare.
As with the ganglion-blocking drugs, the anti-hypertensive effects of adrenergic-neurone-blocking drugs are chiefly seen in the erect position, and postural hypotension commonly occurs. One particular problem with guanethidine, bethanidine, and debrisoquine is that their action is prevented or reversed by tricyclic antidepressant drugs such as imipramine and amitriptyline (Simpson and WaalManning, 1971 ).
Adrenergic Receptor-blocking Drugs
Drugs which prevent or interfere with the release of noradrenaline from the adrenergic neurone such as those described above, block sympathetic activity irrespective of whether the nerve is supplying a or f receptors, and the result is a general reduction in sympathetic activity. Drugs are now available which selectively block a adrenergic receptors and so reduce peripheral vascular resistance and others which block f-receptors, so reducing sympathetic tone on the heart and also reducing sympathetically induced bronchodilatation (Turner, 1974 , it has peripheral effects on blood vessels, reducing their response both to the constrictor effect of noradrenaline and to the dilator action of isoprenaline (Zaimis and Hanington, 1969; Coupar and Kirby, 1972) . This may be the basis of its usefulnes in some patients with migraine. Like some of the adrenergic neurone-blocking drugs, its action can be blocked by tricyclic antidepressant drugs (Briant, Reid, and Dollery, 1973) .
Hydrallazine (Apresoline) is a potent antihypertensive agent, its predominant action being a generalized relaxation of arteriolar smooth muscle. It has a high incidence of undesirable effects, particularly tachycardia and palpitations, but these can be markedly reduced by the combined use of a c adrenergic blocking drug, which also allows a smaller dose of hydrallazine. More dangerous is the production of a hypersensitivity reaction with arthropathy, and, rarely, a syndrome indistinguishable from disseminated lupuserythematosus. Nevertheless, interest in vasodilator drugs, including hydrallazine, has revived in recent years (British Medical Journal, 1973) .
group.bmj.com on October 14, 2017 -Published by http://jcp.bmj.com/ Downloaded from Prazosin (Hypovase) has recently been introduced and is being evaluated. It produces a reduction in total peripheral resistance due, it is thought, to direct relaxation of arteriolar smooth muscle . Sodium nitroprusside, administered by carefully monitored intravenous infusion, has a direct relaxant effect on vascular musculature. The effect is immediate both in onset and offset. It is, therefore, of particular value in the management of very severe hypertension or its acute complications. Long-term effects are due to the accumulation of thiocyanate to which it is converted, and serum levels of the latter should be measured at frequent intervals (Verner, 1974 (1972) suggested that the effectiveness of propranolol in reducing blood pressure in hypertensive patients was closely related to their plasma renin activity, patients with a high renin level showing a uniformly satisfactory response to accepted fl-blocking doses of propranolol, patients with normal levels showing less consistent though still marked responses, and patients with low renin levels showing uniformly ineffective responses. The fall in pressure in the high and normal renin groups correlated well with the fall in plasma renin which occurred. While this offered an interesting and theoretically attractive mechanism for the antihypertensive action of fl-blocking drugs, more recently other investigators, using a larger number of these agents, have not been able to confirm the close relationship between antihypertensive effects and changes in plasma renin activity and urinary aldosterone excretion (Stokes,Weber, and Thornell, 1974) .
CENTRAL MECHANISM
There is increasing evidence that at least part of the therapeutic activity of many antihypertensive drugs is mediated through central nervous system mechanisms. This would not be surprising in view of the side effects upon the central nervous system of drugs such as reserpine, methyldopa, and clonidine. Animal experiments have provided strong evidence for central adrenergic control of blood pressure, with opposing ca and f receptor actions. Stimulation of central ax receptors in cats produces a fall in heart rate and blood pressure while stimulation of f receptors increases heart rate and blood pressure (Day and Roach, 1974) . Destruction of central Paul Turner noradrenergic pathways with 6-hydroxydopamine produces changes in blood pressure consistent with these findings (Lewis, Rawlins, and Reid, 1974) .
It could be postulated that #-blocking drugs might reduce blood pressure, in part at least, by blocking these central f-receptors (Dollery, Lewis, Myers, and Reid, 1973) , Clonidine has been shown to act as an ax receptor agonist on single neurones in the central nervous system, and this could explain at least part of its action (Anderson and Stone, 1974) . The so-called false transmitter cx-methyl-noradrenaline, which accumulates in adrenergic nerves following treatment with methyldopa, has of receptor agonist properties similar to noradrenaline (Coupar and Turner, 1970) , and it could be postulated that stimulation of central a receptors by a methylnoradrenaline might be responsible for at least part of the antihypertensive action of methyldopa (Anden, Butcher, and Engel, 1970) .
Treatment Regimes
While recognizing the need to treat any patient with a blood pressure above the normal range for his or her age and sex, it is important to remember that such treatment may have to continue for many years, and that the patient's cooperation is, therefore, essential. For many people, quality of life is as, if not more, important than its extension by drug treatment, and the mildest form of treatment, with the least unpleasant side effects, which will produce a satisfactory fall in blood pressure, should be used.
MILD-MODERATE HYPERTENSION
In patients with only a modest elevation of pressure and little or no evidence of cardiac, vascular, or renal impairment, a thiazide diuretic or a f-adrenergic-receptor-blocking agent is usually the first drug of choice. If a satisfactory response is not obtained with either of those above mentioned, combined treatment may be used. It may be necessary to increase the dose of the f-blocking drug to high levels before adequate control is obtained, and the pressure may continue to fall slowly for several weeks after a change in dose.
MODERATE-SEVERE HYPERTENSION
The f-receptor blocking drugs may be of value in these patients, but because of the time taken to reach a satisfactory response, it may be desirable to use a more quickly acting drug, particularly in patients with evidence of cardiovascular or renal impairment. Adrenergic-neurone-blocking drugs, vasodilator agents, or clonidine are widely used in these circumstances.
SEVERE HYPERTENSION AND HYPERTENSIVE CRISIS
These conditions require urgent treatment to reduce blood pressure, and intravenous diazoxide or sodium nitroprusside or subcutaneous pentolinium may be used in the most urgent cases. Parenteral methyldopa or reserpine may be given in less urgent circumstances. Intravenous guanethidine may produce an initial increase in pressure before its antihypertensive effect is established, which limits its usefulness in this condition.
The management of essential hypertension is still far from ideal, and it is to be hoped that better understanding of its pathogenesis will lead to the development of more rational and effective treatment which, because of its selectivity of action, will be more easily tolerated by the patient.
